MMED (Minimed Group) Altman Z2-Score: 4.32 (As of Jun. 27, 2026) — 15% Below Median


MMED Minimed Group Inc MMED
15 GF Score
Price $14.28
! 1 Warning Sign
View Full Analysis

What is Minimed Group Altman Z2-Score?

Minimed Group MMED +0.14% 15 Altman Z2-Score is 4.32 as of Jun. 27, 2026, which is 15% below its 10-year median of 5.07. GuruFocus rates MMED with a GF Score™ of 15/100. The stock has 1 warning sign investors should review. Among 845 Medical Devices & Instruments companies, Minimed Group ranks better than 54.91% on this metric.

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Good Sign:

Minimed Group has a Altman Z2-Score of 4.32, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Minimed Group's Altman Z2-Score or its related term are showing as below:

MMED' s Altman Z2-Score Range Over the Past 10 Years
Min: 4.05   Med: 5.07   Max: 6.09
Current: 4.05

During the past 3 years, Minimed Group's highest Altman Z2-Score was 6.09. The lowest was 4.05. And the median was 5.07.


Minimed Group  (NAS:MMED) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Minimed Group Altman Z2-Score Related Terms


Minimed Group Altman Z2-Score Historical Data

* Premium members only.

The historical data trend for Minimed Group's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Minimed Group Altman Z2-Score Chart

Minimed Group Annual Data
Trend Apr23 Apr24 Apr25
Altman Z2-Score
0.00 6.09 4.05

Minimed Group Quarterly Data
Apr24 Jan25 Apr25 Oct25 Jan26
Altman Z2-Score 6.09 0.00 4.05 0.00 0.00

MMED vs ICUI, WRBY, MMSI: Altman Z2-Score Comparison

For the Medical Instruments & Supplies subindustry, Minimed Group's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Minimed Group Altman Z2-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Minimed Group's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Minimed Group's Altman Z2-Score falls into.


MMED
15GF Score
Minimed Group Inc MMED
Altman Z2-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Minimed Group Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Minimed Group's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.0949+3.26*0+6.72*-0.0649+1.05*3.9352
=4.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Jan. 2026:
Total Assets was $4,343 Mil.
Total Current Assets was $1,108 Mil.
Total Current Liabilities was $696 Mil.
Retained Earnings was $0 Mil.
Pre-Tax Income was -99 + 0 + -204 + 21 = $-282 Mil.
Interest Expense was 0 + 0 + 0 + 0 = $0 Mil.
Total Liabilities was $880 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(1108 - 696)/4343
=0.0949

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-282 - 0)/4343
=-0.0649

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Minimed Group has a Altman Z2-Score of 4.32 indicating it is in Safe Zones.

Frequently Asked Questions Learn more about Altman Z2-Score →
What does a Altman Z2-Score of 4.32 mean?
Minimed Group (MMED) has a Altman Z2-Score of 4.32 as of Jun. 27, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Minimed Group and its competitors. This is 15% below median its historical median of 5.07. Over the past decade, Minimed Group's Altman Z2-Score has ranged from 4.05 to 6.09. According to the industry distribution chart, Minimed Group ranks #381 out of 845 companies in the Medical Devices & Instruments industry, placing it in the top 45.1%.
Is Minimed Group's Altman Z2-Score too high?
Minimed Group's current Altman Z2-Score of 4.32 is 15% below median its 10-year median of 5.07. Over the past 10 years, this metric has ranged from a low of 4.05 to a high of 6.09. The Medical Devices & Instruments industry median Altman Z2-Score is 3.48. Minimed Group's value of 4.32 is 24.1% above this industry median. Based on the distribution chart, Minimed Group ranks #381 out of 845 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Minimed Group has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Minimed Group's Altman Z2-Score compare to ICUI and WRBY?
According to the Medical Devices & Instruments industry distribution chart, Minimed Group ranks #381 out of 845 companies for Altman Z2-Score. This puts Minimed Group in the upper half of its industry. The industry median Altman Z2-Score is 3.48. Minimed Group's value of 4.32 is 24.1% above this benchmark. Historically, Minimed Group's own Altman Z2-Score has ranged from 4.05 to 6.09 over the past decade. While the company's 10-year median is 5.07 vs. the industry median of 3.48, Minimed Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Medical Devices & Instruments company?
The median Altman Z2-Score among Medical Devices & Instruments companies is 3.48, based on 845 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Minimed Group's current Altman Z2-Score of 4.32 is 24.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Minimed Group and its competitors. For the Medical Devices & Instruments industry, the median Altman Z2-Score is 3.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Minimed Group's current Altman Z2-Score is 4.32, which is 15% below median its own 10-year median of 5.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Minimed Group stock overvalued right now?
Minimed Group (MMED) has a current Altman Z2-Score of 4.32. The current Altman Z2-Score is 4.32, which is 15% below median its 10-year median of 5.07 and 24.1% above the Medical Devices & Instruments industry median of 3.48. Minimed Group's overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Minimed Group (MMED), the current Altman Z2-Score is 4.32 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Minimed Group Business Description

Other Exchanges B8S:Germany
Address 18000 Devonshire Street, Northridge, CA, USA, 91325
Minimed Group Inc is a medical technology firm that develops, manufactures, and markets products and solutions for diabetes management. It offers automated insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens as its main products. The company sells these through direct-to-consumer channels and healthcare providers of various countries. The company's revenues are principally derived from the sale of reusable and single-use products which together comprise AID systems and smart multiple daily injection (MDI) systems for diabetes management to individuals, distributors, healthcare providers, and other institutions globally.
15GF Score

Get the complete analysis for MMED

Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.28
Price